Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3087186
Max Phase: Preclinical
Molecular Formula: C17H16N2O4
Molecular Weight: 312.32
Molecule Type: Small molecule
Associated Items:
ID: ALA3087186
Max Phase: Preclinical
Molecular Formula: C17H16N2O4
Molecular Weight: 312.32
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: COc1nn(C(C)c2cccc(Oc3ccccc3)c2)c(=O)o1
Standard InChI: InChI=1S/C17H16N2O4/c1-12(19-17(20)23-16(18-19)21-2)13-7-6-10-15(11-13)22-14-8-4-3-5-9-14/h3-12H,1-2H3
Standard InChI Key: NZOZXQFMXHMJPP-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 312.32 | Molecular Weight (Monoisotopic): 312.1110 | AlogP: 3.25 | #Rotatable Bonds: 5 |
Polar Surface Area: 66.49 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 0 |
#RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: | CX LogP: 4.26 | CX LogD: 4.26 |
Aromatic Rings: 3 | Heavy Atoms: 23 | QED Weighted: 0.72 | Np Likeness Score: -0.78 |
1. Patel JZ, Parkkari T, Laitinen T, Kaczor AA, Saario SM, Savinainen JR, Navia-Paldanius D, Cipriano M, Leppänen J, Koshevoy IO, Poso A, Fowler CJ, Laitinen JT, Nevalainen T.. (2013) Chiral 1,3,4-oxadiazol-2-ones as highly selective FAAH inhibitors., 56 (21): [PMID:24083878] [10.1021/jm400923s] |
Source(1):